Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -162.91% is 163% below its 5-year average of -61.98%, near the low end of its 5-year range (-162.91%–-17.93%).
178.86% below its 12-month average of -58.42%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 21.99%.
RETURN ON ASSETS (ROA)
-162.91%
RETURN ON ASSETS (ROA) AVG TTM
-58.42%
RETURN ON ASSETS (ROA) AVG 3Y
-64.67%
RETURN ON ASSETS (ROA) AVG 5Y
-61.98%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-178.86%
CURRENT VS 3Y AVG
-151.91%
CURRENT VS 5Y AVG
-162.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.67%
median of 706 covered companies
CURRENT VS SECTOR MEDIAN
-431.08%
vs the sector median at left
Gossamer Bio, Inc.
Market Cap
$65.26M
Return on Assets (ROA)
-162.91%
TTM Avg
-58.42%
3Y Avg
-64.67%
5Y Avg
-61.98%
Market Cap
$65.80M
Return on Assets (ROA)
-87.09%
TTM Avg
-130.17%
3Y Avg
-272.35%
5Y Avg
-217.34%
Market Cap
$65.15M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
Market Cap
$67.52M
Return on Assets (ROA)
-33.34%
TTM Avg
-56.30%
3Y Avg
-89.26%
5Y Avg
-70.59%
Market Cap
$67.80M
Return on Assets (ROA)
-3.41%
TTM Avg
5.09%
3Y Avg
-8.30%
5Y Avg
-5.06%
Market Cap
$63.78M
Return on Assets (ROA)
-48.60%
TTM Avg
-59.64%
3Y Avg
-46.49%
5Y Avg
-40.66%
Market Cap
$63.75M
Return on Assets (ROA)
-13.50%
TTM Avg
-6.86%
3Y Avg
-33.98%
5Y Avg
-45.40%
Market Cap
$68.93M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$63.23M
Return on Assets (ROA)
-39.17%
TTM Avg
-30.96%
3Y Avg
-31.81%
5Y Avg
-21.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $65.26M | -162.91% | -58.42% | -64.67% | -61.98% |
| Cingulate Inc. (CING)vs › | $65.80M | -87.09% | -130.17% | -272.35% | -217.34% |
| InterCure Ltd. (INCR)vs › | $65.15M | -5.05% | -7.03% | -4.31% | -4.67% |
| iBio, Inc. (IBIO)vs › | $67.52M | -33.34% | -56.30% | -89.26% | -70.59% |
| Champions Oncology, Inc. (CSBR)vs › | $67.80M | -3.41% | 5.09% | -8.30% | -5.06% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | -48.60% | -59.64% | -46.49% | -40.66% |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.75M | -13.50% | -6.86% | -33.98% | -45.40% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.93M | 35.31% | -14.11% | -23.46% | -20.68% |
| Alps Group Inc (ALPS)vs › | $63.23M | -39.17% | -30.96% | -31.81% | -21.33% |
| Kalaris Therapeutics Inc (KLRS)vs › | $62.54M | -44.47% | -42.63% | -230.85% | -167.04% |
ROA
-162.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -98.91% |
| 2024-12-31 | -17.93% |
| 2023-12-31 | -57.65% |
| 2022-12-31 | -84.19% |
| 2021-12-31 | -68.09% |
| 2020-12-31 | -45.11% |
| 2019-12-31 | -42.39% |
| 2018-12-31 | -61.39% |
| 2017-12-31 | -1521.57% |
| 2016-12-31 | -138.33% |
